Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9CWB
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,276
Award facts
- Contract value 100% obligated
- $22,276.07 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 8, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $22,276.07 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors. This firm fixed-price, non-set-aside contract is scheduled for completion by January 9, 2026, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a task order against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive pharmaceutical prime vendor agreement valued at up to $1 billion and extending through December 2026, which enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc. (which operates under the Amerisourcebergen brand name), is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement. The parent company, Cencora, holds the primary $1 billion IDC with DLA through December 31, 2031, demonstrating the company's established capability to efficiently fulfill government contracts for essential pharmaceutical commodities required by military treatment facilities and other federal medical institutions. This delivery order for Dupixent, a specialty medication used in immunological treatments, reflects the company's versatility in fulfilling diverse federal pharmaceutical supply needs across multiple therapeutic domains.
Quick answers
Who was awarded contract SPE2DR26F9CWB?
SPE2DR26F9CWB was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26F9CWB worth?
The government has obligated $22,276 on SPE2DR26F9CWB.
Is contract SPE2DR26F9CWB an order under another contract?
Yes. SPE2DR26F9CWB is a delivery order under SPE2DR25D1017, an indefinite delivery contract.
Was contract SPE2DR26F9CWB competed?
The extent of competition for SPE2DR26F9CWB was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award